Stelara is a brand-name drug prescribed for certain autoimmune conditions. Discover drug interactions in-depth, vaccine interactions, and more.

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Otulfi is supplied as a 45mg/0.5mL and a 90mg/mL single-dose prefilled syringe for subcutaneous injection, a 45mg/0.5mL single-dose vial for subcutaneous injection, and a 130mg/26mL single-dose ...

The U.S. FDA has approved SELARSDI™ as interchangeable with the reference biologic Stelara ® in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is app ...

Selarsdi is FDA-approved in all Stelara-equivalent forms for psoriasis, arthritis, Crohn's, and colitis. Three biosimilar BLAs from Teva-Alvotech are under FDA review, with approvals expected in ...

GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative ...

In December 2024, the FDA approved STEQEYMA in 45mg/0.5mL and 90mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection, and 130mg/26mL in a single-dose vial for intravenous ...

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

GUANGZHOU, China and LONDON, May 27, 2025/ PRNewswire/-- Bio-Thera Solutions, Ltd, a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma ...